Acrux is a pharmaceutical company that specializes in the development, manufacturing, and commercialization of innovative topical medicines. Their products are designed to treat various dermatological and other medical conditions.
Acrux was established in 1998 as a spin-off from CSIRO, the Commonwealth Scientific and Industrial Research Organization in Australia.
The company went public in 2003 and listed on the Australian Securities Exchange (ASX).
Acrux has collaborated with several pharmaceutical companies to develop and commercialize its products.
In 2008, Acrux signed an agreement with Eli Lilly to develop and license a unique transdermal delivery technology called Axiron, a testosterone replacement therapy for men with low testosterone levels.
Acrux has expanded its product portfolio through partnerships with other pharmaceutical companies, focusing on the development of innovative therapeutic solutions.
The company has a strong commitment to research and development, investing in scientific advancements to improve patient outcomes.
Acrux has achieved regulatory approvals for its products in various markets worldwide.
In recent years, Acrux has been actively engaged in the development of generic versions of topical drugs to improve healthcare accessibility and affordability.
Johnson & Johnson is a multinational pharmaceutical and consumer goods company known for its diverse range of products. It has a strong presence in the pharmaceutical market, including topical medications and healthcare products.
GSK is a global healthcare company that manufactures and markets a wide range of pharmaceuticals and consumer health products. They have a significant portfolio of topical medications for various medical conditions.
Pfizer is a multinational pharmaceutical corporation known for its prescription drugs and vaccine products. They have a diverse range of topical medications and dermatological products.
Axiron is a topical solution used for testosterone replacement therapy in men with low testosterone levels.
Acrux develops and commercializes generic versions of various topical medications, providing affordable alternatives for patients.
Acrux offers a range of dermatological products for the treatment of skin conditions such as psoriasis, eczema, and acne.
Acrux is known for its expertise in developing and manufacturing innovative topical medicines for various dermatological and medical conditions.
Axiron is a transdermal testosterone replacement therapy developed by Acrux in collaboration with Eli Lilly. It is used for men with low testosterone levels.
Yes, Acrux develops and commercializes affordable generic versions of topical drugs, enhancing accessibility and affordability of healthcare.
Acrux products can be found in pharmacies and healthcare facilities in various markets worldwide. They may be available under different brand names.
While Acrux offers a range of dermatological products, they are also involved in the development of topical medicines for various medical conditions beyond skincare.